Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters

Archives of Internal Medicine

Volumn 171, Issue 17, 2011, Pages 1560-1569

  Jonsson Funk, Michele ^a   Fusco, Jennifer S ^c   Cole, Stephen R ^a   Thomas, James C ^a   Porter, Kholoud ^d   Kaufman, Jay S ^e   Davidian, Marie ^f   White, Alice D ^a   Hartmann, Katherine E ^g   Eron Jr , Joseph J ^b  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c EpiQuest Sciences Inc   (United States)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

^e MCGILL UNIVERSITY   (Canada)

^f NORTH CAROLINA STATE UNIVERSITY   (United States)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SEROCONVERSION; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80053377142     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.401     Document Type: Article

References (23)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853-860. (Pubitemid 28135961)
2. Cameron DW, Heath-Chiozzi M, Danner S, et al Advanced HIV Disease Ritonavir Study Group. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet. 1998;351(9102):543-549. (Pubitemid 28077559)
3. Hammer SM, Squires KE, Hughes MD, et al AIDS Clinical Trials Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337(11):725-733. (Pubitemid 27417971)
4. Strategic Timing of Antiretroviral Treatment (START) trial: NCT00867048. http: //clinicaltrials.gov/ct2/show/NCT00867048. Accessed July 10, 2011.
5. Kitahata MM, Gange SJ, Abraham AG, et al NA-ACCORD Investigators. Effect ofearly versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815-1826.
6. Sterne JA, May M, Costagliola D, et al When To Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352- 1363.
7. Cain LE, Logan R, Robins JM, et al HIV-CAUSAL Collaboration. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illnesses in HIV-infected persons in developed countries. Ann Intern Med. 2011;154 (8):509-515.
8. Porter K, Babiker A, Bhaskaran K, et al CASCADE Collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet. 2003;362(9392):1267-1274. (Pubitemid 37324254)
9. Hernán MA, Lanoy E, Costagliola D, Robins JM. Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol. 2006;98(3):237-242.
10. Hernán MA, Robins JM, García Rodríguez LA. Discussion on "Statistical issues arising in the Women's Health Initiative." Biometrics. 2005;61(4):922-930. (Pubitemid 43906898)
11. Lee EW, Wei LJ, Amato DA. Cox-type regression analysis for large numbers of small groups of correlated failure time observations. In: Klein JP, Goel PK, eds. Survival Analysis: State of the Art. Dordrecht, Germany: Kluwer Academic Publishers; 1992:237-247.
12. Cole SR, Hernán MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed. 2004;75(1):45-49. (Pubitemid 38648876)
13. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550-560. (Pubitemid 30660034)
14. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656-664.
15. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York, NY: Chapman & Hall; 1993.
16. Mooney C, Duval R. Bootstrapping: A Nonparametric Approach to Statistical Inference. Newbury Park, CA: Sage; 1993.
17. Cole SR, Li R, Anastos K, et al. Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies. Stat Med. 2004;23(21):3351-3363. (Pubitemid 39462092)
18. Sabin CA. Early antiretroviral therapy: the role of cohorts. Curr Opin HIV AIDS. 2009;4(3):200-205.
19. Sinclair JC, Cook RJ, Guyatt GH, Pauker SG, Cook DJ. When should an effective treatment be used? derivation of the threshold number needed to treat and the minimum event rate for treatment. J Clin Epidemiol. 2001;54(3):253-262. (Pubitemid 32153869)
20. Calmy A, Gayet-Ageron A, Montecucco F, et al STACCATO Study Group. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS. 2009;23(8):929-939.
21. El-Sadr WM, Lundgren JD, Neaton JD, et al Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283-2296. (Pubitemid 44837777)
22. Bruyand M, Thiébaut R, Lawson-Ayayi S, et al; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis. 2009;49(7):1109-1116.
23. Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D; Clinical Epidemiology Group of the FHDH-ANRS CO4 Cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009;10(12): 1152-1159.